Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cabrellis Pharmaceuticals raises $27.5mm in Series A round

Executive Summary

Specialty pharma company Cabrellis Pharmaceuticals (cancer drugs; a spin-off of Conforma Therapeutics) raised $27.5mm from a Series A private financing. Investors included Domain Associates, Forward Ventures, Lilly Ventures, Novo AS, ProQuest Investments, RBC Capital Partners, RiverVest Venture Partners, and SR One Ltd.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies